SNSE Sensei Biotherapeutics, Inc.
Price Chart
Executive Summary
Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (Business) in response to SEC staff comments. The amendment expands disclosure around the February 2026 acquisition of Faeth Therapeutics (including its lead asset PIKTOR), the $200M private placement, clinical trial details, and competitive landscape. No financial statements were amended, no restatements were made, and the original financial data remains unchanged.
Actionable Insight
The 10-K/A is purely a disclosure enhancement, not a financial event — no stock-moving catalyst. Monitor Phase 2 endometrial cancer topline data at year-end 2026 and interim Phase 1b breast cancer data in 2027 for meaningful catalysts. Competitive risk from Celcuity's gedatolisib PDUFA date of July 17, 2026 warrants attention.
Key Facts
- Amendment filed solely to revise Business section (Item 1) in response to SEC staff comments
- No financial statements, restatements, or auditor changes were made
- Original 10-K filed March 30, 2026; amendment filed June 2, 2026
- Revised Section 302 certifications (Exhibits 31.3, 31.4) filed with paragraphs 3-5 omitted since no financial or control changes
- Acquisition of Faeth Therapeutics closed February 17, 2026, bringing PIKTOR (oral PI3K/AKT/mTOR inhibitor) into pipeline
- Received $200M gross proceeds from private placement to fund PIKTOR development
- Phase 2 endometrial cancer trial (FTH-PIK-201) topline data expected year-end 2026
- Phase 1b HR+/HER2- breast cancer trial (FTH-PIK-101) first patient dosed May 2026
- Patent portfolio for PIKTOR includes 13 issued U.S. patents with expiration between 2027-2046
- Takeda milestone obligations: up to $119M development/regulatory milestones + up to $250M sales milestones for PIKTOR
Financial Impact
No financial restatement or revision. Filing is administrative — expands business description and pipeline disclosure only.
Risk Factors
- Direct competition from gedatolisib (Celcuity) with FDA decision expected July 17, 2026, and other PI3K/AKT/mTOR candidates in development
- Clinical trial execution risk — PIKTOR data readouts for endometrial (year-end 2026) and breast cancer (2027) may disappoint
- Reliance on Takeda-licensed assets with milestone obligations ($119M + $250M) creating significant future cash commitments if successful
- Pre-revenue clinical-stage biotech with $27M market cap and history of restructuring (65% workforce reduction in Nov 2025)
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-252637 |
| Document: d130328dex313.htm | 0001193125-26-252637 |
| Document: d130328dex314.htm | 0001193125-26-252637 |
| Document: 0001193125-26-252637-index-headers.html | 0001193125-26-252637 |
| Document: 0001193125-26-252637-index.html | 0001193125-26-252637 |
| Document: 0001193125-26-252637.txt | 0001193125-26-252637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
today
|
3
| $13.86 awaiting T+1 | awaiting T+1 | — | $14.53 (+4.83%) |
|
Jun 15, 2026
1d ago
|
8-K
| $13.04 awaiting T+1 | awaiting T+1 | — | $14.53 (−11.43%) |
|
Jun 15, 2026
2d ago
|
EFFECT
| $13.04 awaiting T+1 | awaiting T+1 | — | $14.53 (−11.43%) |
|
Jun 10, 2026
6d ago
|
S-3/A
| $10.79 $13.00 | ▲ +20.48% | ▲ +19.94% | $14.53 (+34.66%) |
|
Jun 10, 2026
6d ago
|
8-K
| $10.79 $13.00 | ▲ +20.48% | ▲ +19.94% | $14.53 (+34.66%) |
|
Jun 2, 2026
14d ago
|
10-K/A
| $16.10 $15.85 | ▼ −1.55% | ▼ −0.86% | $14.53 (−9.72%) |
|
Jun 2, 2026
14d ago
|
S-3/A
| $16.10 $15.85 | ▲ +1.55% | ▲ +0.86% | $14.53 (+9.72%) |
|
Jun 1, 2026
15d ago
|
Insider Cluster
| $16.10 $15.85 | ▲ +1.55% | ▲ +0.83% | $14.53 (+9.72%) |
|
May 22, 2026
25d ago
|
DEFA14A
| $16.47 $15.84 | ▼ −3.83% | ▼ −3.78% | $14.53 (−11.78%) |
|
May 22, 2026
25d ago
|
8-K
| $16.47 $15.84 | ▼ −3.83% | ▼ −3.78% | $14.53 (−11.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access